|Bid||120.3200 x 100|
|Ask||120.3800 x 2000|
|Day's Range||120.3207 - 120.4850|
|52 Week Range||99.8100 - 120.8500|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.07%|
In 2016, BioMarin Pharmaceuticals’ (BMRN) Naglazyme generated revenues of around $297 million, a ~2% year-over-year (or YoY) decline.
These mid-cap growth ETFs can allow you to diversify your risk and achieve strong long-term growth.
Growth stock ETFs can allow you to profit from rapidly-growing companies while diversifying your risk.